Vimarsana
Biggest News Aggregation in the World

Page 3 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 - Vimarsana News

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

HOLON, Israel, Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will...

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer - Vimarsana News

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen.

Source: yahoo.com
Compugen (NASDAQ:CGEN) Downgraded by StockNews.com - Vimarsana News

Compugen (NASDAQ:CGEN) Downgraded by StockNews.com

StockNews.com cut shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a sell rating in a research note released on Thursday. Separately, Stifel Nicolaus upped their price objective on shares of Compugen from $3.00 to $4.00 and gave the company a buy rating in a report on Tuesday, December 19th. Two analysts […]

Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - Vimarsana News

Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target […]

Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial - Vimarsana News

Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial

Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.